SG283G - A phenylalkylaminoethylsalicylamide,its preparation and pharmaceutical compositions containing it - Google Patents

A phenylalkylaminoethylsalicylamide,its preparation and pharmaceutical compositions containing it

Info

Publication number
SG283G
SG283G SG2/83A SG283A SG283G SG 283 G SG283 G SG 283G SG 2/83 A SG2/83 A SG 2/83A SG 283 A SG283 A SG 283A SG 283 G SG283 G SG 283G
Authority
SG
Singapore
Prior art keywords
acid addition
optical isomer
labetalol
protected
phenylalkylaminoethylsalicylamide
Prior art date
Application number
SG2/83A
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of SG283G publication Critical patent/SG283G/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

The (R,R) optical isomer of labetalol, namely 5-[ (R)-1-hydroxy- 2-[(R)-1-methyl- 3-phenylpropyl)amino ]ethyl]salicylamide, and its pharmaceutically acceptable acid addition salts, in a state substantially free of the corresponding (R,S), (S,R) and (S,S) optical isomers, are novel compounds with favourable therapeutic properties in comparison with labetalol. They can be used in particular in the treatment of hypertension. The novel (R,R) optical isomer and its pharmaceutically acceptable acid addition salts can be prepared by removal of the protecting groups from an N,O-protected (R,R) optical isomer or acid addition salt thereof, wherein the basic nitrogen atom and the phenolic hydroxy group are protected, preferably by hydrogenolytic removal of hydrogenolysable groups.
SG2/83A 1978-09-20 1983-01-04 A phenylalkylaminoethylsalicylamide,its preparation and pharmaceutical compositions containing it SG283G (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94451678A 1978-09-20 1978-09-20

Publications (1)

Publication Number Publication Date
SG283G true SG283G (en) 1983-09-16

Family

ID=25481553

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2/83A SG283G (en) 1978-09-20 1983-01-04 A phenylalkylaminoethylsalicylamide,its preparation and pharmaceutical compositions containing it

Country Status (27)

Country Link
EP (1) EP0009702B1 (en)
JP (3) JPS5555147A (en)
KR (2) KR830000904A (en)
AT (1) ATE351T1 (en)
AU (1) AU528626B2 (en)
CA (1) CA1151211A (en)
CY (1) CY1175A (en)
DD (1) DD150457A5 (en)
DE (1) DE2961263D1 (en)
DK (1) DK387579A (en)
FI (1) FI792884A (en)
GR (1) GR73179B (en)
HK (1) HK13383A (en)
HU (1) HU185523B (en)
IE (1) IE49301B1 (en)
IL (1) IL58258A (en)
KE (1) KE3283A (en)
MY (1) MY8500042A (en)
NO (1) NO149660C (en)
NZ (1) NZ191589A (en)
OA (1) OA06339A (en)
PH (1) PH16794A (en)
PL (1) PL129114B1 (en)
PT (1) PT70191A (en)
SG (1) SG283G (en)
YU (1) YU227379A (en)
ZA (1) ZA794872B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4658060A (en) * 1982-04-26 1987-04-14 Schering Corporation Preparation of (-)-5-(beta)-1-hydroxy-2-((beta)-1-methyl-3-phenylpropyl)aminoethyl) salicylamide
IT1194406B (en) * 1983-09-27 1988-09-22 Scharper S P A PROCEDURE FOR THE PREPARATION OF 2-HYDROXY-5-01-HYDROXY-2 - ((4-FENYL-2-BUTYL) AMINO) ETHYL BENZAMIDE
HU190867B (en) * 1984-01-20 1986-11-28 Egyt Gyogyszervegyeszeti Gyar,Hu Process for preparing 2-hydroxy-5-/1-hydroxy-2-/1-methyl-3-phenyl-propyl/-amino/ethyl/-benzamide and pharmaceutically acceptable salts thereof
US4788183A (en) * 1987-11-30 1988-11-29 Schering Corporation Method for treatment of dyslipidemia in humans
US4879233A (en) * 1989-02-10 1989-11-07 Schering Corporation Novel Aspergillus niveus microorganism used for the chiral reduction of carbonyl groups
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
EP1632470A3 (en) * 1991-08-23 2007-07-18 Nps Pharmaceuticals, Inc. Calcium receptor active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
CZ290670B6 (en) 1994-10-21 2002-09-11 Nps Pharmaceuticals, Inc. Compounds, which are able to modulate inorganic ion receptors and pharmaceutical preparation containing thereof
JP4117506B2 (en) * 1996-05-01 2008-07-16 エヌピーエス ファーマシューティカルズ インコーポレイテッド Inorganic ion active compound
IT1313583B1 (en) 1999-07-30 2002-09-09 Chiesi Farma Spa 2-AMINOTETRALINIC DERIVATIVES FOR GLAUCOMA THERAPY.
ATE449062T1 (en) * 2007-02-22 2009-12-15 Indena Spa METHOD FOR PRODUCING (2R,3S)-3-PHENYLISOSERINE METHYL ESTER ACETATE SALT
WO2012021629A2 (en) 2010-08-11 2012-02-16 Philadelphia Health & Education Corporation Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1266058A (en) * 1969-07-08 1972-03-08
US4012444A (en) * 1969-07-08 1977-03-15 Allen & Hanburys Limited 5-[1-Hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl] salicylamide and physiologically acceptable acid addition salts thereof
FR2313074A1 (en) * 1975-04-17 1976-12-31 Scherico Ltd DIASTEROISOMERS OF PHENYLAMINOETHANOL DERIVATIVES

Also Published As

Publication number Publication date
HK13383A (en) 1983-04-29
YU227379A (en) 1983-06-30
NO792993L (en) 1980-03-21
DE2961263D1 (en) 1982-01-14
EP0009702A1 (en) 1980-04-16
ZA794872B (en) 1980-11-26
IL58258A (en) 1984-01-31
CA1151211A (en) 1983-08-02
JPS59108749A (en) 1984-06-23
KR840005307A (en) 1984-11-05
PL129114B1 (en) 1984-03-31
MY8500042A (en) 1985-12-31
GR73179B (en) 1984-02-14
IL58258A0 (en) 1979-12-30
PT70191A (en) 1979-10-01
JPH02167253A (en) 1990-06-27
KR890001998B1 (en) 1989-06-07
HU185523B (en) 1985-02-28
ATE351T1 (en) 1981-11-15
JPH0210128B2 (en) 1990-03-06
KR830000904A (en) 1983-04-28
DD150457A5 (en) 1981-09-02
NO149660C (en) 1984-05-30
AU5088179A (en) 1980-03-27
AU528626B2 (en) 1983-05-05
IE49301B1 (en) 1985-09-18
KE3283A (en) 1983-05-13
JPS5555147A (en) 1980-04-22
NO149660B (en) 1984-02-20
NZ191589A (en) 1984-03-30
IE791770L (en) 1980-03-20
EP0009702B1 (en) 1981-11-04
CY1175A (en) 1983-06-10
FI792884A (en) 1980-03-21
DK387579A (en) 1980-03-21
OA06339A (en) 1981-06-30
PL218408A1 (en) 1980-09-08
PH16794A (en) 1984-02-28

Similar Documents

Publication Publication Date Title
DE2961263D1 (en) A phenylalkylaminoethylsalicylamide, its preparation and pharmaceutical compositions containing it
AU683442B2 (en) Aminoacid derivates, medicaments containing these compounds and process for preparing the same
CA2092794A1 (en) Naphthylalkylamines, process for their preparation and pharmaceutical compositions that contain them
ES8506729A1 (en) New cephem compounds and processes for preparation thereof.
CA2029657A1 (en) Compositions and their use in lowering intraocular pressure
PT90022A (en) PROCESS FOR THE PREPARATION OF CEFEM DERIVATIVES AND CORRESPONDING INTERMEDIARIES
MY111055A (en) Pharmaceutical composition and process for the preparation thereof
ATE48001T1 (en) CEPHEM COMPOUNDS, PROCESSES FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL PREPARATIONS.
IL124296A0 (en) Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase
WO1990003172A3 (en) Bile acids for treatment of viral infections
DE3060423D1 (en) Dipeptides for use in the treatment of diseases, some compounds of this class, medicaments containing dipeptides and their manufacture
ES524375A0 (en) A PROCEDURE FOR PREPARING A PIRIDYLALKYL NITRATE COMPOUND
ES2065855A1 (en) Desoxyazaphospholipid derivatives having inhibiting activity on phospholipase a2
IL69448A (en) Process for combating phytopathogenic fungi with azolylphenoxy-tetrahydrofuran-2-ylidene methane derivatives
ES8400397A1 (en) New peptide, process for preparation thereof and use thereof.
DK105183D0 (en) METHOD OF PREPARING 1,4-DIAMINOCYCLITOL DERIVATIVES
ES8403135A1 (en) Penicillin derivatives.
JPS5540601A (en) New 3-(3,4-dihydroxyphenyl)serine derivative
ZA933942B (en) Pyrrolothienopyrazine compounds, processes for the preparation thereof and pharmaceutical compositions containing them